Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

APPEAL · Antivirus Pandemic Preparedness EuropeAn pLatform

HORIZONStatus: SIGNED1 January 202431 December 2028EU funding €7,565,674Call HORIZON-HLTH-2023-DISEASE-03

Developing new antiviral treatment against viruses and particularly high-priority emerging and re-emerging viruses as listed by the WHO, remains crucial as, among other aspects, the viruses evolve under selection. Broad spectrum host-directed antiviral drugs (HDA) are promising therapeutic options, however the robust identification of relevant host factors by genome-wide knockout screens is challenging due to low consistency in the resulting hits. Our project aims to (1) establish a computational and experimental pipeline to identify and validate an antiviral for these viruses, and (2) identify at least one broad spectrum antiviral drug against potential emerging and re-emerging viruses as listed by the WHO. To address these, we will implement a drug selection pipeline following several strategies: We will employ (i) machine learning, based on data from knockout screens, proteomics, protein interaction, transcriptomics of infected cells with pandemic-related viruses, Genome-Wide Association Studies, and generic gene descriptors, (ii) High Density Cell Arrays, which provide much more detailed readouts compared to state of the art pooled knockout screens, (iii) primary cell cultures obtained from a diverse array of human tissues, as they are more appropriate to study the host cell physiology during infection, compared to cancer cell lines, and (iv) use the pipeline to identify host restriction factors, which, when activated, challenge the virus; followed by innovative drug development and delivery based on small activating RNA. The pipeline comprises an Expedited Arm for which broad spectrum antiviral drugs for repurposing will be selected followed by in vitro and in vivo efficacy testing, and a clinical trial as a proof of concept. The elaborated Arm includes all strategies (i)-(iv) and will provide a sustainable pandemic preparedness pipeline ready-to-operate to identify the appropriate treatment against the emerging virus at the early time of a new outbreak.

Consortium · 15 organisations

coordinator

UNIVERSITATSKLINIKUM JENA

DE · €1,714,516

participant

ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK

FR · €54,375

associatedPartner

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

UK

participant

CONSULTECH TECHNOLOGIEBERATUNG GMBH

DE · €429,375

participant

UNIVERSITATSMEDIZIN GREIFSWALD KORPERSCHAFT DES OFFENTLICHEN RECHTS

DE · €337,589

participant

MATTEK IN VITRO LIFE SCIENCE LABORATORIES SRO

SK · €663,750

participant

TECHNISCHE UNIVERSITAET MUENCHEN

DE · €554,146

participant

RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

DE · €797,125

participant

EUROPEAN RESEARCH INFRASTRUCTURE ON HIGHLY PATHOGENIC AGENTS

BE · €532,896

participant

PHARMAI DISCOVERY GMBH

DE · €226,993

participant

INSTITUT PASTEUR

FR · €1,104,730

participant

JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN

DE · €69,825

participant

ACONDICIONAMIENTO TARRASENSE ASSOCIACION

ES · €363,438

thirdParty

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

NL

participant

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

FR · €716,915

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.